# Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED

> **NCT00492635** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 628 (actual)

## Conditions studied

- Erectile Dysfunction
- Sexual Dysfunction, Physiological

## Interventions

- **DRUG:** Levitra (Vardenafil, BAY38-9456)
- **DRUG:** Levitra (Vardenafil, BAY38-9456)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00492635
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 628 (ACTUAL)
- **Last updated:** 2014-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00492635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00492635, "Study to Compare the Tolerability and Efficacy of Once Daily Vardenafil vs Vardenafil PRN vs Placebo in Men Immediately After Nerve-sparing Prostatectomy for Improving ED". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00492635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*